001     125283
005     20240228145520.0
024 7 _ |a 10.1002/ijc.30828
|2 doi
024 7 _ |a pmid:28597939
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:20942792
|2 altmetric
037 _ _ |a DKFZ-2017-01421
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Horak, Peter
|0 0000-0003-4536-9306
|b 0
|e First author
245 _ _ |a Precision oncology based on omics data: The NCT Heidelberg experience.
260 _ _ |a Bognor Regis
|c 2017
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1660743417_10248
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Precision oncology implies the ability to predict which patients will likely respond to specific cancer therapies based on increasingly accurate, high-resolution molecular diagnostics as well as the functional and mechanistic understanding of individual tumors. While molecular stratification of patients can be achieved through different means, a promising approach is next-generation sequencing of tumor DNA and RNA, which can reveal genomic alterations that have immediate clinical implications. Furthermore, certain genetic alterations are shared across multiple histologic entities, raising the fundamental question of whether tumors should be treated by molecular profile and not tissue of origin. We here describe MASTER (Molecularly Aided Stratification for Tumor Eradication Research), a clinically applicable platform for prospective, biology-driven stratification of younger adults with advanced-stage cancer across all histologies and patients with rare tumors. We illustrate how a standardized workflow for selection and consenting of patients, sample processing, whole-exome/genome and RNA sequencing, bioinformatic analysis, rigorous validation of potentially actionable findings, and data evaluation by a dedicated molecular tumor board enables categorization of patients into different intervention baskets and formulation of evidence-based recommendations for clinical management. Critical next steps will be to increase the number of patients that can be offered comprehensive molecular analysis through collaborations and partnering, to explore ways in which additional technologies can aid in patient stratification and individualization of treatment, to stimulate clinically guided exploratory research projects, and to gradually move away from assessing the therapeutic activity of targeted interventions on a case-by-case basis toward controlled clinical trials of genomics-guided treatments.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Klink, Barbara
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Heining, Christoph
|0 P:(DE-He78)1464357f7ec5faf677a390a414e50c88
|b 2
700 1 _ |a Gröschel, Stefan
|0 P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f
|b 3
700 1 _ |a Hutter, Barbara
|0 P:(DE-He78)135e8c8d1dd1b66b8127c3d1e3a9b6a0
|b 4
700 1 _ |a Fröhlich, Martina Antonia
|0 P:(DE-He78)a15aa7d740f286aad9d8139d515e866c
|b 5
700 1 _ |a Uhrig, Sebastian
|0 P:(DE-He78)a8e85c1bd89741ab0c2a28032ba81359
|b 6
700 1 _ |a Hübschmann, Daniel
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Schlesner, Matthias
|0 P:(DE-He78)f2a782242acf94a3114d75c45dc75b37
|b 8
700 1 _ |a Eils, Roland
|0 P:(DE-He78)78b6aa82148e60b4d91e3a37a6d3d9a0
|b 9
700 1 _ |a Richter, Daniela
|0 P:(DE-He78)29306fd3ae9f1a9839ed888ebc5c8074
|b 10
700 1 _ |a Pfütze, Katrin
|0 P:(DE-He78)83906db1355a576371363a4b9f107d3d
|b 11
700 1 _ |a Geörg, Christina
|0 P:(DE-He78)3f888debb126ff36634df058ccaaf2b4
|b 12
700 1 _ |a Meißburger, Bettina
|0 P:(DE-He78)9437a8b804d8cc2481997716ec66fa2f
|b 13
700 1 _ |a Wolf, Stephan
|0 P:(DE-He78)1efb774993effe7a66a6ffc1b1cf9ccb
|b 14
700 1 _ |a Schulz, Angela
|0 P:(DE-He78)a0494aed1057846ea6c9bc93cacbe8e2
|b 15
700 1 _ |a Penzel, Roland
|b 16
700 1 _ |a Herpel, Esther
|b 17
700 1 _ |a Kirchner, Martina
|0 P:(DE-He78)3b9d10db5dbbf9eb21d02f77d99c8ac9
|b 18
|u dkfz
700 1 _ |a Lier, Amelie
|0 P:(DE-He78)f2177f299ad93efd161811e331914297
|b 19
|u dkfz
700 1 _ |a Endris, Volker
|b 20
700 1 _ |a Singer, Stephan
|b 21
700 1 _ |a Schirmacher, Peter
|0 P:(DE-HGF)0
|b 22
700 1 _ |a Weichert, Wilko
|0 P:(DE-HGF)0
|b 23
700 1 _ |a Stenzinger, Albrecht
|0 P:(DE-HGF)0
|b 24
700 1 _ |a Schlenk, Richard
|0 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc
|b 25
700 1 _ |a Schröck, Evelin
|0 P:(DE-HGF)0
|b 26
700 1 _ |a Brors, Benedikt
|0 P:(DE-He78)fc949170377b58098e46141d95c72661
|b 27
700 1 _ |a von Kalle, Christof
|0 P:(DE-He78)5bacb661d5d7c0220d8f996d980ad8de
|b 28
700 1 _ |a Glimm, Hanno
|0 P:(DE-He78)157277fe62f07df1732f9d126a51d1b9
|b 29
700 1 _ |a Fröhling, Stefan
|0 0000-0001-7907-4595
|b 30
|e Last author
773 _ _ |a 10.1002/ijc.30828
|g Vol. 141, no. 5, p. 877 - 886
|0 PERI:(DE-600)1474822-8
|n 5
|p 877 - 886
|t International journal of cancer
|v 141
|y 2017
|x 0020-7136
909 C O |p VDB
|o oai:inrepo02.dkfz.de:125283
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 0000-0003-4536-9306
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)1464357f7ec5faf677a390a414e50c88
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)135e8c8d1dd1b66b8127c3d1e3a9b6a0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)a15aa7d740f286aad9d8139d515e866c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)a8e85c1bd89741ab0c2a28032ba81359
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)f2a782242acf94a3114d75c45dc75b37
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)78b6aa82148e60b4d91e3a37a6d3d9a0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)29306fd3ae9f1a9839ed888ebc5c8074
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)83906db1355a576371363a4b9f107d3d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)3f888debb126ff36634df058ccaaf2b4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)9437a8b804d8cc2481997716ec66fa2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)1efb774993effe7a66a6ffc1b1cf9ccb
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)a0494aed1057846ea6c9bc93cacbe8e2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)3b9d10db5dbbf9eb21d02f77d99c8ac9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)f2177f299ad93efd161811e331914297
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 23
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 25
|6 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 26
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 27
|6 P:(DE-He78)fc949170377b58098e46141d95c72661
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 28
|6 P:(DE-He78)5bacb661d5d7c0220d8f996d980ad8de
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 29
|6 P:(DE-He78)157277fe62f07df1732f9d126a51d1b9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 30
|6 0000-0001-7907-4595
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Translational cancer research
|x 0
914 1 _ |y 2017
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2015
920 1 _ |0 I:(DE-He78)G100-20160331
|k G100
|l Translationale Onkologie
|x 0
920 1 _ |0 I:(DE-He78)L301-20160331
|k L301
|l DKTK Dresden
|x 1
920 1 _ |0 I:(DE-He78)G240-20160331
|k G240
|l Molekulare Leukämogenese
|x 2
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 3
920 1 _ |0 I:(DE-He78)G200-20160331
|k G200
|l Angewandte Bioinformatik
|x 4
920 1 _ |0 I:(DE-He78)B080-20160331
|k B080
|l Theoretische Bioinformatik
|x 5
920 1 _ |0 I:(DE-He78)B069-20160331
|k B069
|l B069 Zentrum für personalisierte Medizin
|x 6
920 1 _ |0 I:(DE-He78)W190-20160331
|k W190
|l Hochdurchsatz-Sequenzierung
|x 7
920 1 _ |0 I:(DE-He78)L701-20160331
|k L701
|l DKTK München
|x 8
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G100-20160331
980 _ _ |a I:(DE-He78)L301-20160331
980 _ _ |a I:(DE-He78)G240-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)G200-20160331
980 _ _ |a I:(DE-He78)B080-20160331
980 _ _ |a I:(DE-He78)B069-20160331
980 _ _ |a I:(DE-He78)W190-20160331
980 _ _ |a I:(DE-He78)L701-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21